PBS listing changes effective 1 May 2025
21 May 2025
Update
Services Australia have announced recent changes to Pharmaceutical Benefits Scheme (PBS) effective from 1 May 2025. This includes listings relevant to psychiatric practice reprinted below:
- Schizophrenia
Aripiprazole (720 mg/2.4 mL modified release injection, 2.4mL syringe; 960 mg/3.2 mL modified release injection, 3.2mL syringe; (Abilify Asimtufii®) is now listed on the PBS for the treatment of schizophrenia. Prescriptions for treatment are Authority required (STREAMLINED). - Treatment resistant major depression
Esketamine (28 mg/2 actuations nasal spray, 2 actuations; 28 mg/2 actuations nasal spray, 2 x 2 actuations; 28 mg/2 actuations nasal spray, 3 x 2 actuations) (Spravato®) is now listed on the PBS for the treatment of treatment resistant major depression. Authority applications for initial (induction), grandfather and continuing (non-induction) treatments can be made either in real-time using the Online PBS Authorities system of by telephone.
Further details about these and other listing changes are available via the PBS website.
More news & views

President's Column June 2025
June has been an exceptionally busy month for the mental health sector, marked by successive budgets...
25 June 2025
Psychiatry Interest Forum (PIF) Program at Congress 2025
Forty-one (41) PIF medical students and junior doctors were fully supported to attend the Congress i...
24 June 2025
CPD Evaluation survey 2025
A survey on the RANZCP CPD Program is open until 18 July 2025. Any information you provide is anonym...